Drug intelligence / Profile preview

P3F1 392-510 peptide mimics

Development stage
Preclinical
Lead developer
California Institute of Technology
Modality
Peptides
01

Overview

P3F1 392-510 peptide mimics are experimental therapeutic agents designed to target the PAX3::FOXO1 (P3F1) fusion oncoprotein, the primary driver of fusion-positive alveolar rhabdomyosarcoma (aRMS). These peptides are modeled after a specific intrinsically disordered region (IDR) of P3F1, specifically residues 392-510, which has been identified as a critical hub for protein-protein interactions and transcriptional activity. By mimicking this sequence, the peptides aim to disrupt the formation of neomorphic transcriptional hubs and the recruitment of coactivators like p300, thereby suppressing P3F1-mediated gene expression and tumor cell proliferation. The design of these mimics is informed by the cationic and aromatic residue composition of the 392-510 region, which facilitates cation-π and π-π interactions essential for hub formation.

Other names
P3F1 IDR mimetic peptidesP-3F1 IDR mimetic peptidesP 3F1 IDR mimetic peptidesPAX3::FOXO1 392-510 peptide mimicsPAX3-FOXO1 392-510 peptide mimicsPAX-3-FOXO1 392-510 peptide mimicsPAX 3-FOXO1 392-510 peptide mimics
02

Targets

PAX7-FOXO1 (PAX7-FOXO1 fusion protein)

Beyond the preview

Go deeper on P3F1 392-510 peptide mimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on P3F1 392-510 peptide mimics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call